ADJUVANT THERAPY;
ARTICLE;
BREAST CANCER;
COMPARATIVE STUDY;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG ADMINISTRATION;
DRUG DELIVERY DEVICE;
DRUG DOSAGE FORM COMPARISON;
EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER;
HAND HELD SYRINGE;
HEALTH CARE PERSONNEL;
HUMAN;
METHODOLOGY;
MOTION;
MULTICENTER STUDY;
MULTIPLE CYCLE TREATMENT;
PRIORITY JOURNAL;
PROSPECTIVE STUDY;
SINGLE USE INJECTION DEVICE;
TIME;
TIME AND MOTION STUDY;
BREAST NEOPLASMS;
CLINICAL TRIAL;
FEMALE;
GENETICS;
INTRAVENOUS DRUG ADMINISTRATION;
SUBCUTANEOUS DRUG ADMINISTRATION;
TASK PERFORMANCE;
TREATMENT OUTCOME;
ANTINEOPLASTIC AGENTS;
BREAST NEOPLASMS;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
INJECTIONS, INTRAVENOUS;
INJECTIONS, SUBCUTANEOUS;
PROSPECTIVE STUDIES;
RECEPTOR, ERBB-2;
TIME AND MOTION STUDIES;
TRASTUZUMAB;
TREATMENT OUTCOME;
GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available at(accessed 18 January 2016).
Ferlay, J., I. Soerjomataram, M. Ervik, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available at http://globocan.iarc.fr (accessed 18 January 2016).
National Comprehensive Cancer Network. 2016. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. V1.2016. Available at http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf (accessed 12 January 2016).
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., S. Kyriakides, S. Ohno, et al. 2015. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26:v8-30.
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Coates, A.S., E. P. Winer, A. Goldhirsch, et al. 2015. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann. Oncol. 26:1533-1546.
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial
Ismael, G., R. Hegg, S. Muehlbauer, et al. 2012. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 13:869-878.
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males
Wynne, C., R. B. Ellis-Pegler, D. S. Waaka, et al. 2013. Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males. Cancer Chemother. Pharmacol. 72:1079-1087.
Herceptin. Summary of product characteristics. Available at(18 January 2016).
European Medicines Agency. Herceptin. Summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPARProduct_Information/human/000278/WC500074922.pdf (18 January 2016).
8
84883049426
Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study
Pivot, X., J. Gligorov, V. Müller, et al. 2013. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 14:962-970.
Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study
Pivot, X., J. Gligorov, V. Müller, et al. 2014. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann. Oncol. 25:1979-1987.
Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study
Fallowfield, L., S. Osborne, C. Langridge, K. Monson, J. Kilkerr, V. Jenkins et al. 2013. Reasons for patients' preferences for subcutaneous or intravenous trastuzumab in the PrefHer study. Eur. J. Cancer 49:S385.
